Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
about
PI3K/PTEN signaling in angiogenesis and tumorigenesisPI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen PeroxideTargeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphomaSystematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL)Phosphorylation of eukaryotic translation initiation factor 4B (EIF4B) by open reading frame 45/p90 ribosomal S6 kinase (ORF45/RSK) signaling axis facilitates protein translation during Kaposi sarcoma-associated herpesvirus (KSHV) lytic replicationTumor vascular changes mediated by inhibition of oncogenic signaling.Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.Rapalogs in viral cancers.Kaposi's sarcoma-associated herpesvirus G-protein coupled receptor activates the canonical Wnt/β-catenin signaling pathway.Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors.Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.Roles of host and viral microRNAs in human cytomegalovirus biologyDisrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma.Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.Measuring and interpreting the selectivity of protein kinase inhibitorsmTOR pathway in colorectal cancer: an update.New drug targets in Kaposi sarcoma.Advances in the systemic treatment of cutaneous sarcomas.Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?Hijacking GPCRs by viral pathogens and tumor.Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor.The Viral G Protein-Coupled Receptor ORF74 Hijacks β-Arrestins for Endocytic Trafficking in Response to Human Chemokines.Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
P2860
Q28383083-E8D2C14B-F217-407E-AC14-DF726FAC33EAQ28553400-04165B57-A4B7-44EC-B7C0-058E6AFE7EF7Q30409463-7655016B-346D-42FC-8419-520482AF2007Q30414412-BF94252D-F06B-42A8-893D-D2ABCFB47CFDQ30423529-7E6FFF99-4586-4AC9-94BA-1596368AD760Q33671385-5FEEC5AB-985E-4279-A5FA-FD127BB51965Q33819076-FF9EA8EB-6123-47C2-B163-C4E9E32268C4Q33826815-A4BAD007-BE8B-4E61-95AA-7F42295D14D6Q34160579-CD249A44-365C-4645-B307-C1EBA445F931Q35006465-C66D4248-D3F9-45D0-A19F-C663B9FC4061Q35158385-D1E8747C-D2F3-4973-8AF6-668C0E630AA4Q35177682-F2390E3F-388A-46BE-A9B5-3397C1E04D14Q35208091-EC612143-A9CA-4165-8104-0681716D8820Q35453657-77D19549-47CB-47E0-9582-B1F4CB43F3AEQ35827892-C1D5A094-6D29-49C9-A318-921F8B8FD658Q36060243-FF2D8F31-23B0-41BE-BA9D-1CE5E95FAC51Q36340825-A0EC51ED-2DBE-42F5-92F9-0F652F39AD9BQ37331742-411BC8AA-89FB-4EAA-84E7-E01C290DF003Q37537075-C7ACF805-A72E-45E5-9A53-40D55CF43AA8Q37649634-3997B764-A2D0-4010-B473-62BABD4CA6A0Q37806235-9C3F948F-FCEB-4ED1-BDBB-1F0D35B46412Q38000872-0D3FDF2F-BE49-4BEC-9D6A-ABA8C0699168Q38180332-3D22F82C-865E-41C6-B695-84BEA771BAA0Q38802773-0BF4279E-86BF-41BD-A187-90BA09AFA917Q39515479-515FE2A0-857E-4B2C-A6B0-C8563B1E3700Q39659259-F6666C54-0434-4C36-B4DD-696B1502EC30Q39806707-64FABE09-EA3C-40BE-830A-2920D4C016B3Q51020785-8EE0C0EA-2AB3-4EEF-A12E-F6D76CC404ABQ57072192-D8D533F1-749D-4A63-8A61-5799EF020D51
P2860
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@en
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@nl
type
label
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@en
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@nl
prefLabel
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@en
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@nl
P2093
P2860
P1433
P1476
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
@en
P2093
Bruno C Jham
Kevan M Shokat
Risa Chaisuparat
Silvia Montaner
P2860
P304
P356
10.1158/0008-5472.CAN-08-0878
P407
P577
2008-10-01T00:00:00Z